Chronic Kidney Disease(CKD)RESET-CKDNCT06754280
An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease
A study testing RESET-CKD in people with Chronic Kidney Disease(CKD), run by University of Illinois Chicago at 1 site in United States.
Trial summary
RESET-CKD is evaluating an intervention to support Black adults with chronic kidney disease (CKD) to reduce their sedentary (e.g., sitting) time. Half of the participants will be randomized to the intervention, where the goal is to support individuals to reduce their sitting time, and the other half will be randomized… Read more about this study
- Who is it for?
- Ages 35 to 80 years
- Conditions the study is for
- Chronic Kidney Disease(CKD)
- What is being tested?
- RESET-CKD
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Mar 2025to May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Self-identifies as Black or African American
- Age ≥35 to ≤80 years old
- CKD Stage 1-4
- Self-reported 6 or more hours/day of sedentary time
- Ability to speak/read/understand English
- Has access to a telephone
Who cannot join
- Being unable to walk 1 block
- Being unable to stand from a seated position without assistance
- Using a wheelchair, walker, or cane for all of their ambulation
- Presence of a condition(s) or diagnosis, either physical or psychological, that precludes participation, including: Lower-extremity amputation (AKA or BKA) without prosthetic, Orthopedic condition that would preclude prompted sit-to-stand transitions or standing, Neurologic or psychiatric condition that would preclude prompted sit-to- stand transitions or standing, Severe cognitive impairment, Unstable coronary artery disease (i.e., angina with activity), Orthostatic hypotension
- Kidney transplant
- Any other condition that the investigator considers precludes participation in the trial
- Participated in the Patient Advisory Board
Trial locations and contacts
1 site in 1 country.
United States1 site
UI Health/University of Illinois Chicago
Chicago, Illinois, 60612
About this study
Official title: An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease: RESET-CKD
RESET-CKD is evaluating an intervention to support Black adults with chronic kidney disease (CKD) to reduce their sedentary (e.g., sitting) time. Half of the participants will be randomized to the intervention, where the goal is to support individuals to reduce their sitting time, and the other half will be randomized to an attention control condition that provides CKD-related education not related to sedentary behavior. All participants will be followed for 12 weeks.
- Conditions
- Chronic Kidney Disease(CKD)
- Being tested
- RESET-CKD, Attention Control
- Keywords
- Sedentary
- Medical subject headings
- Renal Insufficiency, Chronic, Sedentary Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RESET-CKDBehavioural
RESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues.
Attention ControlOther
CKD-related education
| Study group | Role | What they receive |
|---|---|---|
| RESET-CKD | Experimental | RESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues. Receives: Behavioral: RESET-CKD |
| Attention Control | Active comparator | CKD-related education Receives: Other: Attention Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in sedentary time
Change in activPAL-measured sedentary time
Measured: Baseline to week 12
Secondary outcomes (2)
Change in self-reported sedentary time
Change in self-reported sedentary time
Measured: Baseline to week 12
Change in health-related quality of life
Change in health-related quality of life measured via the KDQOL
Measured: Baseline to week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Dec 2024
- Study start13 Mar 2025
- Primary completionDec 2026 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney Disease(CKD)Studies of the same condition, open and under way.
- More trials run by University of Illinois ChicagoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Illinois Chicago
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Nursing Research (NINR)
- Responsible party
- Principal investigator, Mary Hannan, University of Illinois Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06754280
- Sponsor's protocol ID
- 2024-1410
- Other IDs
- K23NR021034
- Acronym
- RESET-CKD
- Status last verified
- Aug 2026
- First submitted
- 23 Dec 2024
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Intervention to Reduce Sedentary Behavior for Adults With Chronic Kidney Disease: RESET-CKD
- ClinicalTrials.gov ID
- NCT06754280
- Acronym / sponsor ID
- RESET-CKD / 2024-1410
- Conditions
- Chronic Kidney Disease(CKD)
- Keywords
- Sedentary
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University of Illinois ChicagoUniversity, hospital or other
- Collaborators
- National Institute of Nursing Research (NINR)
- Study start
- 13 Mar 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 31 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RESET-CKD is evaluating an intervention to support Black adults with chronic kidney disease (CKD) to reduce their sedentary (e.g., sitting) time. Half of the participants will be randomized to the intervention, where the goal is to support individuals to reduce their sitting time, and the other half will be randomized to an attention control condition that provides CKD-related education not related to sedentary behavior. All participants will be followed for 12 weeks.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| RESET-CKD | Experimental | Behavioral: RESET-CKDRESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues. |
| Attention Control | Active comparator | Other: Attention ControlCKD-related education |
Who may qualify
- Ages
- 35 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Self-identifies as Black or African American
- Age ≥35 to ≤80 years old
- CKD Stage 1-4
- Self-reported 6 or more hours/day of sedentary time
- Ability to speak/read/understand English
Key exclusion criteria (7 listed)
- Being unable to walk 1 block
- Being unable to stand from a seated position without assistance
- Using a wheelchair, walker, or cane for all of their ambulation
- Presence of a condition(s) or diagnosis, either physical or psychological, that precludes participation, including: Lower-extremity amputation (AKA or BKA) without prosthetic, Orthopedic condition that would preclude prompted sit-to-stand transitions or standing, Neurologic or psychiatric condition that would preclude prompted sit-to- stand transitions or standing, Severe cognitive impairment, Unstable coronary artery disease (i.e., angina with activity), Orthostatic hypotension
- Kidney transplant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RESET-CKDRESET-CKD is a 12-week intervention that consists of four major components to support decreasing sedentary behavior: (1) health coaching, (2) feedback charts on sedentary behavior, (3) a workbook, and (4) reminders and cues. | Behavioural | RESET-CKD |
| Attention ControlCKD-related education | Other | Attention Control |
Primary outcome
Change in sedentary time
Time frame: Baseline to week 12
Change in activPAL-measured sedentary time
2 secondary outcomes
Change in self-reported sedentary time
Time frame: Baseline to week 12
Change in health-related quality of life
Time frame: Baseline to week 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
Related trials for Chronic Kidney Disease(CKD)
Not yet recruiting
SWitching to Appropriate Prescription in Cardiovascular-Kidney-Metabolic Syndrome
Cardiovascular-kidney-metabolic Syndrome, Diabete Type 2
RecruitingPhase 2
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
Chronic Kidney Disease
Not yet recruitingPhase 2
Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease
Chronic Kidney Disease (CKD)
Not yet recruitingEarly Phase 1
Sarcopenia in Chronic Kidney Disease (CKD) Patients
Chronic Kidney Disease, Sarcopenia
Active, not recruitingPhase 4
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
Chronic Kidney Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing RESET-CKD in people with Chronic Kidney Disease(CKD), run by University of Illinois Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in sedentary time (time frame: Baseline to week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.